validate a criterion for AS eligibility based on tumour clinical size and age on a cohort of patients treated with surgery.
INTRODUCTION AND OBJECTIVES: Radical nephrectomy (RN) is the preferred treatment of small renal masses (SRM) in renal transplant candidates. Given the high risk of surgical complications in this cohort, active surveillance (AS) may be an option as many lesions are indolent. Since data on the use of AS in this setting is lacking, we surveyed transplant surgeons across the US on their institutional practice patterns for treatment of SRM.
METHODS: A 21-question online survey designed to analyze practice patterns of SRM management in renal transplant recipient candidates was sent to active transplant centers in the US. The list of recipients to whom the survey was distributed was obtained with permission from the American Society of Transplant Surgeons. All respondents were de-identified and consented to participate.
RESULTS:
We received 62 responses from 53 US Transplant Centers. All 11 United Network of Organ Sharing (UNOS) regions were represented. 38.7% (n¼24) indicated that their institution does not follow formal guidelines for treatment of SRM. The majority (85.5%, n¼53) indicated that their institution screens for renal masses in candidates for renal transplantation. RN was the preferred treatment (59%, n¼61), followed by AS (21.3%, n¼13), partial nephrectomy (14.8%, n¼9) and focal ablative therapy (4.9%, n¼3). Additionally, 14.5% (n¼9) respondents routinely perform renal mass biopsy before any decision is made. Although the majority of centers prefer definitive treatment, 27% allow AS prior to transplantation. For those institutions that allow AS, 95.5% felt comfortable if mass was <1 cm, 41.7% if <2 cm and 20.8% if 2-4 cm. Among institutions that allow AS, none alter their immunosuppressive regimen. Amongst the responders whose institutions did not allow active surveillance, 77.4% indicated that if presented with longterm data showing safety of AS, they would perform immediate transplantation and monitor SRM in these patients.
CONCLUSIONS: Variations in practice patterns suggest the need for standardized guidelines in the management of SRM in renal transplant candidates. Though RN is the preferred treatment, most transplant surgeons would consider AS if long term safety data were available.
Source of Funding: None

PD59-10 THE NATURAL HISTORY OF LARGE RENAL MASSES ON ACTIVE SURVEILLANCE & EXPECTANT MANAGEMENT
Karim Marzouk*, Amy Tin, Nick Liu, Daniel Sjoberg, A. Ari Hakimi, Paul Russo, Jonathan Coleman, New York City, NY INTRODUCTION AND OBJECTIVES: Surgical intervention is the standard of care for large renal masses; however patients with competing risks may not be suitable candidates for immediate intervention. This study illustrates our experience with active surveillance (AS) and expectant management of large renal masses (LRM) 4cm. We describe the growth rate of LRM under surveillance, factors associated with growth rate, and overall outcomes.
METHODS: Our institutional database identified 101 patients with renal masses 4.0cm between 1993 and 2016. Inclusion criteria were those followed with serial imaging for at least 6 months without surgical intervention. Bosniak 1-2 cysts and clinically benign renal masses such as angiomyolipomas were excluded from analysis. We used ordinal least squares regression to calculate LRM growth rate (cm/ year) for each patient based on maximal diameter. Univariate linear regression was used to assess whether clinical factors were associated with growth rate and competing risk methods were used to estimate the probability of developing RCC metastasis in the setting of death from other causes.
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